Citations

Showing 10 of 108162 citations.

Ethanol Biomarker Testing and Challenges
Snozek, Christine L.H. , Souers, Rhona J., Dizon, Annabel, Magnani, B, Krasowski, Matthew D. , Krasowski, Matthew D , Magnani, Barbarajean

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 26, 2021 | Volume: 145 | Issue: 12 | Pages: 1492-1498

10.5858/arpa.2020-0699-cp | PMID 33635953 Get It

Context.— Clinical and forensic testing for ethanol biomarkers, including ethyl glucuronide (EtG) and ethyl sulfate (EtS), is used to discern alcohol use from abstinence. These markers can be key in major decisions, including transplant eligibility or retaining licensure after alcohol misuse. Accuracy, precision, and recognition of the implications of reporting cutoffs are all essential for correct interpretation. Objective.— To evaluate trends in testing for EtG and EtS, including how laboratories perform testing and how comparable participant results are. Design.— The study examined the College of American Pathologists ethanol biomarker proficiency testing survey from 2013 to 2019. Trends in methodology, reporting cutoffs, and participant performance were evaluated for qualitative and quantitative EtG testing and for quantitative EtS testing. Results.— There was little consensus in reporting cutoffs, which ranged from 10 to 1000 ng/mL for EtG and 10 to 1500 ng/mL for EtS. Although median EtG and EtS compared well with target concentrations, individual participants' results varied widely. For quantitative enzyme immunoassay, accuracy and precision were best in EtG challenges less than 1500 ng/mL. For EtG or EtS by mass spectrometry, overall accuracy was good over a wide concentration range, but variability between participants was high. Approximately 10% (409 of 4059) of results were unacceptable, which for mass spectrometry corresponded to more than 35% above or below the group mean. Conclusions.— Although many participants performed well, there was insufficient consensus in reporting cutoffs, and a consistent fraction of laboratories failed to achieve survey standards. Guidelines for assay performance and reporting could greatly benefit laboratories and end users.
Risk of Conversion to Arthroplasty After Hip Arthroscopy: Validation of a Published Risk Score Using an Independent, Prospectively Collected Database
Leland, Devin P. , Lall, Ajay C. , Domb, Benjamin G. , Hartigan, David E. , Levy, Bruce A. , Krych, Aaron J. , Krych, Aaron J , Hevesi, Mario , Rosinsky, Philip J.

Mayo Clinic

The American Journal of Sports Medicine | February 26, 2021 | Volume: 49 | Issue: 5 | Pages: 1192-1198

10.1177/0363546521993829 | PMID 33635085 Get It

Background: Hip arthroscopy is rapidly advancing and increasingly commonly performed. The most common surgery after arthroscopy is total hip arthroplasty (THA), which unfortunately occurs within 2 years of arthroscopy in up to 10% of patients. Predictive models for conversion to THA, such as that proposed by Redmond et al, have potentially substantial value in perioperative counseling and decreasing early arthroscopy failures; however, these models need to be externally validated to demonstrate broad applicability. Purpose: To utilize an independent, prospectively collected database to externally validate a previously published risk calculator by determining its accuracy in predicting conversion of hip arthroscopy to THA at a minimum 2-year follow-up. Study Design: Cohort study (diagnosis); Level of evidence, 1. Methods: Hip arthroscopies performed at a single center between November 2015 and March 2017 were reviewed. Patients were assessed pre- and intraoperatively for components of the THA risk score studied—namely, age, modified Harris Hip Score, lateral center-edge angle, revision procedure, femoral version, and femoral and acetabular Outerbridge scores—and followed for a minimum of 2 years. Conversion to THA was determined along with the risk score’s receiver operating characteristic (ROC) curve and Brier score calibration characteristics. Results: A total of 187 patients (43 men, 144 women, mean age, 36.0 ± 12.4 years) underwent hip arthroscopy and were followed for a mean of 2.9 ± 0.85 years (range, 2.0-5.5 years), with 13 patients (7%) converting to THA at a mean of 1.6 ± 0.9 years. Patients who converted to THA had a mean predicted arthroplasty risk of 22.6% ± 12.0%, compared with patients who remained arthroplasty-free with a predicted risk of 4.6% ± 5.3% ( P < .01). The Brier score for the calculator was 0.04 ( P = .53), which was not statistically different from ideal calibration, and the calculator demonstrated a satisfactory area under the curve of 0.894 ( P < .001). Conclusion: This external validation study supported our hypothesis in that the THA risk score described by Redmond et al was found to accurately predict which patients undergoing hip arthroscopy were at risk for converting to subsequent arthroplasty, with satisfactory discriminatory, ROC curve, and Brier score calibration characteristics. These findings are important in that they provide surgeons with validated tools to identify the patients at greatest risk for failure after hip arthroscopy and assist in perioperative counseling and decision making.
Use of bioimpedance spectroscopy for prospective surveillance and early diagnosis of breast cancer–related lymphedema
Forte, Antonio J. , Huayllani, María T. , Kassis, Salam Al, Ciudad, Pedro , Lu, Xiaona , Moore, Pamela A., McLaughlin, Sarah A. , Boczar, Daniel , Ávila, Francisco R. , Forte, Antonio Jorge

Mayo Clinic

Breast Disease | February 26, 2021 | Volume: 40 | Issue: 2 | Pages: 85-93

10.3233/bd-201008 | PMID 33646139 Get It

BACKGROUND: Bioimpedance spectroscopy has been suggested as a useful tool for early diagnosis of breast cancer–related lymphedema (BCRL). We aimed to describe the outcomes of published studies that evaluated bioimpedance analysis as a method for prospective surveillance and early diagnosis of BCRL. METHODS: We queried the PubMed, Ovid Medline, and EMBASE databases to identify studies that evaluated use of bioimpedance spectroscopy as a diagnostic tool. We used the keywords “bioimpedance” AND (“lymphedema” OR “lymphoedema”) in the search. Only English-language studies that reported quantitative outcomes for patients with BCRL were included. RESULTS: Of 152, 235 and 116 identified articles in PubMed, Ovid Medline and EMBASE databases, only 22 were included. Use of bioimpedance analysis for prospective surveillance has been shown to prevent chronic BCRL. All the cross-sectional and retrospective studies that evaluated bioimpedance for diagnosis of BCRL reported significantly different L-Dex scores between lymphedema patients and healthy participants; in addition, bioimpedance scores were positively correlated with volume of lymphedema. CONCLUSION: Bioimpedance analysis is a potential tool with demonstrated benefits for prevention of chronic BCRL and may be an economic and great alternative for early diagnosis of BCRL.
Unique Challenges Faced by Women in Mohs Micrographic Surgery: A Survey of Members of the American College of Mohs Surgery
Baker, Catherine , Dwan, Dennis , Chen, Youdinghuan , Vidal, Nahid Y. , Hamann, Carsten R.

Mayo Clinic

Dermatologic Surgery | February 26, 2021 | Volume: 47 | Issue: 7 | Pages: 1007-1008

10.1097/dss.0000000000002914 | PMID 33587383 Get It

Lawsonella clevelandensis: an emerging cause of vascular graft infection
Ramesh, Rommel , Assi, Mariam , Garrigos, Zerelda Esquer , Sohail, M. Rizwan , Esquer Garrigos, Zerelda , Sohail, M Rizwan

Mayo Clinic

BMJ Case Reports | February 26, 2021 | Volume: 14 | Issue: 2 | Pages: e237350

10.1136/bcr-2020-237350 | PMID 33637490 Get It

Lawsonella clevelandensis, an emerging pathogen, was first described in 2016, and has been implicated in abdominal, breast and spinal abscesses in a limited number of cases. Being a fastidious organism, it is primarily identified with molecular methods. With the incorporation of broad-range PCR testing in clinical diagnostics, L. clevelandensis has been increasingly reported in the literature. We describe a case of a 65-year-old man who presented with bilateral psoas abscesses secondary to aorto-bi-iliac vascular graft infection with L. clevelandensis identified using 16S rRNA/PCR sequencing. The patient underwent surgical resection and replacement of infected graft, followed by 6 weeks of intravenous antibiotic therapy and then chronic suppression with doxycycline and cefadroxil. He was infection-free at last follow-up.
Application of 3D Printing in Preoperative Planning
Segaran, Nicole , Saini, Gia , Mayer, Joseph L. , Naidu, Sailen G., Patel, Indravadan , Alzubaidi, Sadeer , Öklü, Rahmi , Naidu, Sailen, Oklu, Rahmi , Naidu, Sailendra

Mayo Clinic

Journal of Clinical Medicine | February 26, 2021 | Volume: 10 | Issue: 5 | Pages: 917

10.3390/jcm10050917 | PMID 33652844 Get It

Preoperative planning is critical for success in the surgical suite. Current techniques for surgical planning are limited; clinicians often rely on prior experience and medical imaging to guide the decision-making process. Furthermore, two-dimensional (2D) presentations of anatomical structures may not accurately portray their three-dimensional (3D) complexity, often leaving physicians ill-equipped for the procedure. Although 3D postprocessed images are an improvement on traditional 2D image sets, they are often inadequate for surgical simulation. Medical 3D printing is a rapidly expanding field and could provide an innovative solution to current constraints of preoperative planning. As 3D printing becomes more prevalent in medical settings, it is important that clinicians develop an understanding of the technologies, as well as its uses. Here, we review the fundamentals of 3D printing and key aspects of its workflow. The many applications of 3D printing for preoperative planning are discussed, along with their challenges.
LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repair
Chen, Lifeng , Hou, Jing , Zeng, Xiangyu , Tu, Xinyi , Zhao, Fei , Wu, Zheming , Huang, Jinzhou , Luo, Kuntian, Kim, Wootae , Guo, Qiang , Kloeber, Jake A. , Lou, Zhenkun , Kim, Wootae , Zeng, Xiangyu , Guo, Qiang, Deng, Min , Lou, Zhenkun

Mayo Clinic

Clinical and Translational Medicine | February 26, 2021 | Volume: 11 | Issue: 3 | Pages: No page available

10.1002/ctm2.341 | PMID 33784003 Get It

Abstract PARP inhibitors induce DNA lesions, the repair of which are highly dependent on homologous recombination (HR), and preferentially kill HR‐ deficient cancers. However, cancer cells have developed several mechanisms to transform HR and confer drug resistance to PARP inhibition. Therefore, there is a great clinical interest in exploring new therapies that induce HR deficiency (HRD), thereby sensitizing cancer cells to PARP inhibitors. Here, we found that GSK2578215A, a high‐selective and effective leucine‐rich repeat kinase 2 (LRRK2) inhibitor, or LRRK2 depletion suppresses HR preventing the recruitment of RAD51 to DNA damage sites through disruption of the interaction of RAD51 and BRCA2. Moreover, LRRK2 inhibition or depletion increases the susceptibility of ovarian cancer cells to Olaparib in vitro and in vivo. In clinical specimens, LRRK2 high expression is high related with advanced clinical characteristics and poor survival of ovarian cancer patients. All these findings indicate ovarian cancers expressing high levels of LRRK2 are more resistant to treatment potentially through promoting HR. Furthermore, combination treatment with an LRRK2 and PARP inhibitor may be a novel strategy to improve the effectiveness of LRRK2 expression ovarian cancers.
Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction
Verbrugge, Frederik H. , Reddy, Yogesh N.V. , Sorimachi, Hidemi, Omote, Kazunori , Carter, Rickey E. , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A , Carter, Rickey E , Verbrugge, Frederik H

Mayo Clinic

European Journal of Heart Failure | February 26, 2021 | Volume: 23 | Issue: 6 | Pages: 954-963

10.1002/ejhf.2142 | PMID 33634544 Get It

Aims To investigate the prognostic value of diagnostic scores for heart failure (HF) with preserved ejection fraction (HFpEF). Methods and results Consecutive patients with HFpEF admitted for unequivocal decompensated HF treated with intravenous loop diuretics were evaluated ( n = 443; mean age 78 ± 12 years; 60% women). The HFA‐PEFF and H 2 FPEF scores were calculated for all patients with echocardiography data available within 1 year and the population was stratified according to HFA‐PEFF scores 2–4 ( n = 79), 5 ( n = 93), or 6 ( n = 271) and H 2 FPEF score probabilities <90% ( n = 80), 90–95% ( n = 61), and 96–100% ( n = 293). HF readmission rates (95% confidence intervals) increased from 28.9 (22.7–35.0) per 100 patient‐years in HFA‐PEFF 2–4 to 46.0 (38.5–53.5) in HFA‐PEFF 5 and 45.0 (40.1–49.8) in HFA‐PEFF 6. Similarly, HF readmission rates increased with increasing H 2 FPEF probability: <0.90 [31.8 (25.3–38.2) per 100 patient‐years], 0.90–0.95 [41.5 (32.9–50.1)], and 0.96–1.00 [45.9 (41.2–50.6]. Median survival was 65 months (36–89 months) in HFA‐PEFF score 2–4, 45 months (26–59 months) in HFA‐PEFF score 5, and 28 months (22–42 months) in HFA‐PEFF score 6 ( P < 0.001), while the hazard ratio (95% confidence interval) for all‐cause mortality was 1.16 (1.02–1.32) per 0.10 increase in H 2 FPEF probability. Conclusions Among patients hospitalized with HFpEF, higher HFpEF probability according to diagnostic scores is associated with increased risk of subsequent HF readmissions and all‐cause mortality.
Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1
Krabill, Aaron D. , Chen, Hao , Hewitt, Chad S. , Imhoff, Ryan D. , Muli, Christine S. , Das, Chittaranjan , Galardy, Paul J. , Wendt, Michael K. , Flaherty, Daniel P. , Imhoff, Ryan D , Das, Chittaranjan , Wendt, Michael K , Flaherty, Daniel P , Hussain, Sajjad

Mayo Clinic

Molecules | February 26, 2021 | Volume: 26 | Issue: 5 | Pages: 1227

10.3390/molecules26051227 | PMID 33668938 Get It

The deubiquitinating enzyme (DUB) UCHL1 is implicated in various disease states including neurodegenerative disease and cancer. However, there is a lack of quality probe molecules to gain a better understanding on UCHL1 biology. To this end a study was carried out to fully characterize and optimize the irreversible covalent UCHL1 inhibitor VAEFMK. Structure-activity relationship studies identified modifications to improve activity versus the target and a full cellular characterization was carried out for the first time with this scaffold. The studies produced a new inhibitor, 34, with an IC50 value of 7.7 µM against UCHL1 and no observable activity versus the closest related DUB UCHL3. The molecule was also capable of selectively inhibiting UCHL1 in cells and did not demonstrate any discernible off-target toxicity. Finally, the molecule was used for initial probe studies to assess the role of UCHL1 role in proliferation of myeloma cells and migration behavior in small cell lung cancer cells making 34 a new tool to be used in the biological evaluation of UCHL1.
Analysis of 20-Year Trends in Medicare Reimbursement for Reconstructive Microsurgery
Teven, Chad M. , Yu, Jason , Abujbarah, Sami , Chow, Nathan , Casey, William J., Rebecca, Alanna M. , Yu, Jason W , Chow, Nathan A, Chow, Nathan A , Gupta, Nikita

Mayo Clinic

Journal of Reconstructive Microsurgery | February 26, 2021 | Volume: 37 | Issue: 08 | Pages: 662-670

10.1055/s-0041-1724128 | PMID 33634443 Get It

Abstract Background Microsurgery is being increasingly utilized across surgical specialties, including plastic surgery. Microsurgical techniques require greater time and financial investment compared with traditional methods. This study aimed to evaluate 20-year trends in Medicare reimbursement and utilization for commonly billed reconstructive microsurgery procedures from 2000 to 2019. Methods Microsurgical procedures commonly billed by plastic surgeons were identified. Reimbursement data were extracted from The Physician Fee Schedule Look-Up Tool from the Centers for Medicare and Medicaid Services for each current procedural terminology (CPT) code. All monetary data were adjusted for inflation to 2019 U.S. dollars. The average annual and total percentage changes in reimbursement were calculated based on these adjusted trends. To assess utilization trends, CMS physician/supplier procedure summary files were queried for the number of procedures billed by plastic surgeons from 2010 to 2018. Results After adjusting for inflation, the average reimbursement for all procedures decreased by 26.92% from 2000 to 2019. The greatest mean decrease was observed in CPT 20969 free osteocutaneous flaps with microvascular anastomosis (−36.93%). The smallest mean decrease was observed in repair of blood vessels with vein graft (−9.28%). None of the included procedures saw an increase in reimbursement rate over the study period. From 2000 to 2019, the adjusted reimbursement rate for all procedures decreased by an average of 1.35% annually. Meanwhile, the number of services billed to Medicare by plastic surgeons across the included CPT codes increased by 42.17% from 2010 to 2018. Conclusion This is the first study evaluating 20-year trends in inflation-adjusted Medicare reimbursement and utilization in reconstructive microsurgery. Reimbursement for all included procedures decreased over 20% during the study period, while number of services increased. Increased consideration of these trends will be important for U.S. policymakers, hospitals, and surgeons to assure continued access and reconstructive options for patients.